北京万泰生物药业股份有限公司关于选举职工代表董事的公告

Core Points - The company held its second extraordinary general meeting on November 28, 2025, where it approved the proposal to cancel the supervisory board and amend the Articles of Association [1][5] - Chen Hao was elected as the employee representative director of the sixth board of directors, ensuring compliance with relevant laws and regulations [2][4] Group 1: Meeting Details - The extraordinary general meeting took place on November 28, 2025, at the company's conference room in Beijing [6] - The meeting was chaired by the company's chairman, Qiu Zixin, and utilized a combination of on-site and online voting [7] Group 2: Resolutions Passed - The following proposals were approved during the meeting: 1. Cancellation of the supervisory board and amendment of the Articles of Association 2. Revision of the related party transaction management system 3. Revision of the board meeting rules 4. Revision of the shareholders' meeting rules 5. Revision of the independent director work system 6. Revision of the cumulative voting implementation details [8][9] Group 3: Legal Compliance - The meeting was witnessed by Beijing Zhonglun Law Firm, confirming that all procedures and voting results complied with legal and regulatory requirements [9]